Literature DB >> 11765049

Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas.

C Asteria1, M Anagni, L Persani, P Beck-Peccoz.   

Abstract

Thyrotropin-secreting pituitary adenomas (TSH-omas) are rare tumors (0.5% of all pituitary adenomas) showing an invasive behavior and usually sporadic, although a few cases are associated with multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant inherited syndrome. This disorder is linked to loss of heterozygosity (LOH) on 11q13 and inactivating mutations of MEN1 gene, which is located in the same chromosomal region. As other types of anterior pituitary adenomas, TSH-omas are the result of a monoclonal outgrowth where the intrinsic genetic defects involving oncogenes or tumor suppressor genes occur in a progenitor cell. However, so far no activating mutations of particular oncogenes or inactivating mutations of tumor suppressor genes have been identified. Starting from the observation that 3-30% of sporadic pituitary adenomas show LOH on 11q13, and that allelic losses on the long arms of chromosome 11, beside 10 and 13, are significantly associated with the transition from the non-invasive to the invasive phenotype, we decided to investigate LOH on 11q13 and mutations of menin in a large series of TSH-omas. Thirteen tumors were evaluated. DNA was extracted from tumors by standard methods and genomic DNA from peripheral blood leukocytes was used as control. LOH was screened by using 3 polymorphic markers on 11q13: D11S956, PYGM, INT-2. In 3 out of 15 cases we could demonstrate LOH on 11q13, but none of the tumors showed menin mutation after sequence analysis. These data strongly suggest that menin does not play a causative role in the development of TSH-omas, and are in agreement with other studies demonstrating a limited role of menin in pituitary sporadic tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11765049     DOI: 10.1007/BF03343929

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  25 in total

1.  GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

Authors:  C A Landis; S B Masters; A Spada; A M Pace; H R Bourne; L Vallar
Journal:  Nature       Date:  1989-08-31       Impact factor: 49.962

2.  Positional cloning of the gene for multiple endocrine neoplasia-type 1.

Authors:  S C Chandrasekharappa; S C Guru; P Manickam; S E Olufemi; F S Collins; M R Emmert-Buck; L V Debelenko; Z Zhuang; I A Lubensky; L A Liotta; J S Crabtree; Y Wang; B A Roe; J Weisemann; M S Boguski; S K Agarwal; M B Kester; Y S Kim; C Heppner; Q Dong; A M Spiegel; A L Burns; S J Marx
Journal:  Science       Date:  1997-04-18       Impact factor: 47.728

3.  Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes.

Authors:  Q Dong; F Brucker-Davis; B D Weintraub; R C Smallridge; F E Carr; J Battey; A M Spiegel; A Shenker
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

4.  Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis.

Authors:  J Poncin; A Stevenaert; A Beckers
Journal:  Eur J Endocrinol       Date:  1999-06       Impact factor: 6.664

5.  Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors.

Authors:  T R Prezant; J Levine; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

6.  Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours.

Authors:  M Delhase; P Vergani; A Malur; B Velkeniers; E Teugels; J Trouillas; E L Hooghe-Peters
Journal:  J Mol Endocrinol       Date:  1993-10       Impact factor: 5.098

7.  GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas.

Authors:  N Sanno; A Teramoto; A Matsuno; S Takekoshi; R Y Osamura
Journal:  J Clin Endocrinol Metab       Date:  1995-08       Impact factor: 5.958

8.  Molecular genetic studies of sporadic pituitary tumors.

Authors:  M D Boggild; S Jenkinson; M Pistorello; M Boscaro; M Scanarini; P McTernan; C W Perrett; R V Thakker; R N Clayton
Journal:  J Clin Endocrinol Metab       Date:  1994-02       Impact factor: 5.958

9.  c-myc, c-fos, and c-myb gene expression in human pituitary adenomas.

Authors:  M Woloschak; J L Roberts; K Post
Journal:  J Clin Endocrinol Metab       Date:  1994-07       Impact factor: 5.958

10.  Clonal origin of pituitary adenomas.

Authors:  V Herman; J Fagin; R Gonsky; K Kovacs; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

View more
  4 in total

1.  2013 European thyroid association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors.

Authors:  P Beck-Peccoz; A Lania; A Beckers; K Chatterjee; J-L Wemeau
Journal:  Eur Thyroid J       Date:  2013-05-07

Review 2.  Genetic mutations in sporadic pituitary adenomas--what to screen for?

Authors:  Anne-Lise Lecoq; Peter Kamenický; Anne Guiochon-Mantel; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2014-10-28       Impact factor: 43.330

Review 3.  Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

Authors:  Fatemeh G Amlashi; Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-21       Impact factor: 3.633

Review 4.  Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease.

Authors:  Marta Migocka-Patrzałek; Magdalena Elias
Journal:  Cells       Date:  2021-04-13       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.